Angus Toland
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 8 | 2026 | 1325 | 1.350 |
Why?
| | Meningioma | 2 | 2021 | 87 | 1.210 |
Why?
| | Meningeal Neoplasms | 2 | 2021 | 95 | 1.210 |
Why?
| | Glioma | 3 | 2026 | 425 | 0.920 |
Why?
| | Biomarkers, Tumor | 6 | 2026 | 1339 | 0.880 |
Why?
| | Spinal Cord Neoplasms | 3 | 2023 | 40 | 0.860 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2024 | 54 | 0.820 |
Why?
| | Chondrosarcoma | 1 | 2022 | 17 | 0.720 |
Why?
| | Fibroma | 1 | 2022 | 21 | 0.710 |
Why?
| | Mutation | 7 | 2026 | 4093 | 0.690 |
Why?
| | Osteosarcoma | 1 | 2022 | 100 | 0.670 |
Why?
| | Bone Neoplasms | 1 | 2022 | 272 | 0.590 |
Why?
| | Astrocytoma | 3 | 2026 | 128 | 0.580 |
Why?
| | DNA Methylation | 3 | 2026 | 725 | 0.440 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2025 | 125 | 0.370 |
Why?
| | Neoplasm Grading | 3 | 2026 | 313 | 0.260 |
Why?
| | Brain Diseases, Metabolic, Inborn | 1 | 2026 | 6 | 0.240 |
Why?
| | Lung Neoplasms | 3 | 2025 | 2675 | 0.240 |
Why?
| | Succinate Dehydrogenase | 1 | 2026 | 65 | 0.230 |
Why?
| | Malformations of Cortical Development | 1 | 2026 | 20 | 0.230 |
Why?
| | Muscle Spasticity | 1 | 2026 | 63 | 0.230 |
Why?
| | Fallopian Tube Neoplasms | 1 | 2025 | 20 | 0.230 |
Why?
| | Folate Receptor 1 | 1 | 2025 | 17 | 0.230 |
Why?
| | Submandibular Gland | 1 | 2025 | 20 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2025 | 22 | 0.220 |
Why?
| | Interleukin-5 | 1 | 2025 | 39 | 0.220 |
Why?
| | Carcinosarcoma | 1 | 2025 | 23 | 0.220 |
Why?
| | Churg-Strauss Syndrome | 1 | 2025 | 27 | 0.220 |
Why?
| | Perivascular Epithelioid Cell Neoplasms | 1 | 2024 | 2 | 0.220 |
Why?
| | Immunohistochemistry | 3 | 2025 | 1712 | 0.210 |
Why?
| | Humans | 33 | 2026 | 146342 | 0.210 |
Why?
| | Sequence Analysis, DNA | 2 | 2026 | 771 | 0.210 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2025 | 90 | 0.210 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2024 | 21 | 0.210 |
Why?
| | Neuroblastoma | 1 | 2026 | 177 | 0.200 |
Why?
| | Adrenoleukodystrophy | 1 | 2024 | 9 | 0.200 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2024 | 56 | 0.200 |
Why?
| | Fatal Outcome | 1 | 2024 | 302 | 0.200 |
Why?
| | Teratoma | 1 | 2025 | 121 | 0.200 |
Why?
| | Proof of Concept Study | 1 | 2024 | 90 | 0.200 |
Why?
| | Anus Neoplasms | 1 | 2024 | 33 | 0.200 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 192 | 0.200 |
Why?
| | Drug Resistant Epilepsy | 1 | 2026 | 145 | 0.200 |
Why?
| | Cauda Equina | 1 | 2023 | 6 | 0.200 |
Why?
| | Tumor Suppressor Proteins | 2 | 2026 | 315 | 0.190 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2023 | 38 | 0.190 |
Why?
| | Lymphoproliferative Disorders | 1 | 2023 | 59 | 0.190 |
Why?
| | Carcinoma, Small Cell | 1 | 2023 | 172 | 0.190 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 76 | 0.190 |
Why?
| | Single-Cell Analysis | 2 | 2026 | 370 | 0.180 |
Why?
| | Polyomavirus | 1 | 2022 | 10 | 0.180 |
Why?
| | Polyomavirus Infections | 1 | 2022 | 29 | 0.180 |
Why?
| | Atlases as Topic | 1 | 2022 | 10 | 0.180 |
Why?
| | Nonlinear Optical Microscopy | 1 | 2022 | 1 | 0.180 |
Why?
| | Cells | 1 | 2022 | 24 | 0.180 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2025 | 992 | 0.180 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2024 | 268 | 0.180 |
Why?
| | Gangliosides | 1 | 2022 | 23 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 102 | 0.180 |
Why?
| | B7-H1 Antigen | 1 | 2024 | 245 | 0.170 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 195 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 1 | 2024 | 177 | 0.170 |
Why?
| | Peripheral Nerves | 1 | 2022 | 73 | 0.170 |
Why?
| | Organ Specificity | 1 | 2022 | 307 | 0.170 |
Why?
| | Brain Stem Neoplasms | 1 | 2022 | 86 | 0.170 |
Why?
| | Neural Stem Cells | 1 | 2023 | 167 | 0.170 |
Why?
| | Ependymoma | 1 | 2023 | 177 | 0.160 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 70 | 0.160 |
Why?
| | Sarcoma, Clear Cell | 1 | 2020 | 10 | 0.160 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2021 | 131 | 0.160 |
Why?
| | RNA Splicing | 1 | 2022 | 288 | 0.160 |
Why?
| | Male | 16 | 2026 | 73396 | 0.160 |
Why?
| | Disease Susceptibility | 1 | 2022 | 339 | 0.150 |
Why?
| | Survival Rate | 2 | 2026 | 2092 | 0.150 |
Why?
| | Prognosis | 3 | 2026 | 4351 | 0.150 |
Why?
| | Papillomavirus Infections | 1 | 2024 | 345 | 0.150 |
Why?
| | DNA | 1 | 2026 | 1421 | 0.150 |
Why?
| | Ovarian Neoplasms | 1 | 2025 | 604 | 0.150 |
Why?
| | Cholecystitis | 1 | 2019 | 25 | 0.140 |
Why?
| | Neurons | 2 | 2025 | 1668 | 0.140 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 271 | 0.140 |
Why?
| | Hematologic Diseases | 1 | 2019 | 66 | 0.140 |
Why?
| | Needles | 1 | 2019 | 61 | 0.140 |
Why?
| | Transcriptome | 2 | 2022 | 1068 | 0.140 |
Why?
| | Brain | 4 | 2026 | 2991 | 0.140 |
Why?
| | Female | 15 | 2026 | 79499 | 0.140 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 356 | 0.130 |
Why?
| | Specimen Handling | 1 | 2019 | 178 | 0.130 |
Why?
| | Child | 8 | 2026 | 22693 | 0.120 |
Why?
| | Child, Preschool | 5 | 2026 | 11913 | 0.120 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 170 | 0.120 |
Why?
| | Histones | 1 | 2022 | 670 | 0.120 |
Why?
| | Prostatic Neoplasms | 1 | 2023 | 972 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 640 | 0.120 |
Why?
| | Adolescent | 7 | 2026 | 22557 | 0.120 |
Why?
| | Adult | 10 | 2026 | 41087 | 0.110 |
Why?
| | RNA | 1 | 2022 | 926 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2022 | 641 | 0.110 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2026 | 71 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1512 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2024 | 6460 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1160 | 0.100 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 1468 | 0.100 |
Why?
| | Melanoma | 1 | 2020 | 765 | 0.100 |
Why?
| | Molecular Typing | 1 | 2013 | 21 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2020 | 806 | 0.100 |
Why?
| | Escherichia coli Infections | 1 | 2013 | 125 | 0.090 |
Why?
| | Middle Aged | 9 | 2026 | 36619 | 0.090 |
Why?
| | Drug Resistance, Bacterial | 1 | 2013 | 185 | 0.090 |
Why?
| | Astrocytes | 2 | 2023 | 229 | 0.080 |
Why?
| | Neoplasms | 2 | 2026 | 2954 | 0.080 |
Why?
| | Nuclear Proteins | 2 | 2026 | 740 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 747 | 0.070 |
Why?
| | Microglia | 2 | 2022 | 289 | 0.070 |
Why?
| | Escherichia coli | 1 | 2013 | 832 | 0.070 |
Why?
| | Mice | 5 | 2025 | 18297 | 0.070 |
Why?
| | Infant | 4 | 2026 | 10114 | 0.070 |
Why?
| | Aged | 6 | 2026 | 26432 | 0.060 |
Why?
| | X-linked Nuclear Protein | 1 | 2026 | 9 | 0.060 |
Why?
| | DNA Modification Methylases | 1 | 2026 | 19 | 0.060 |
Why?
| | DNA Repair Enzymes | 1 | 2026 | 29 | 0.060 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 3545 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2026 | 74 | 0.060 |
Why?
| | Succinic Acid | 1 | 2026 | 46 | 0.060 |
Why?
| | Tissue Array Analysis | 1 | 2025 | 49 | 0.060 |
Why?
| | Maytansine | 1 | 2025 | 18 | 0.060 |
Why?
| | CpG Islands | 1 | 2026 | 175 | 0.060 |
Why?
| | Young Adult | 4 | 2026 | 14330 | 0.060 |
Why?
| | DNA Helicases | 1 | 2026 | 138 | 0.050 |
Why?
| | Paracrine Communication | 1 | 2025 | 67 | 0.050 |
Why?
| | Vagus Nerve | 1 | 2025 | 92 | 0.050 |
Why?
| | Angiomyolipoma | 1 | 2024 | 21 | 0.050 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2024 | 37 | 0.050 |
Why?
| | Eye Neoplasms | 1 | 2024 | 31 | 0.050 |
Why?
| | Acetyl-CoA C-Acyltransferase | 1 | 2023 | 2 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2025 | 138 | 0.050 |
Why?
| | Animals | 5 | 2025 | 38107 | 0.050 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2025 | 195 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2026 | 441 | 0.050 |
Why?
| | Anal Canal | 1 | 2024 | 101 | 0.050 |
Why?
| | Glutamic Acid | 1 | 2025 | 255 | 0.050 |
Why?
| | beta Catenin | 1 | 2025 | 250 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2024 | 209 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2026 | 539 | 0.050 |
Why?
| | Microscopy | 1 | 2024 | 147 | 0.050 |
Why?
| | Endothelium | 1 | 2022 | 119 | 0.040 |
Why?
| | Spectrum Analysis, Raman | 1 | 2022 | 36 | 0.040 |
Why?
| | Neuroglia | 1 | 2023 | 177 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2026 | 1242 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2026 | 1488 | 0.040 |
Why?
| | Pericytes | 1 | 2022 | 42 | 0.040 |
Why?
| | Synapses | 1 | 2025 | 448 | 0.040 |
Why?
| | Genomics | 1 | 2026 | 853 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2025 | 536 | 0.040 |
Why?
| | California | 1 | 2022 | 475 | 0.040 |
Why?
| | Biopsy | 1 | 2024 | 1075 | 0.040 |
Why?
| | Myelin Sheath | 1 | 2022 | 166 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2024 | 525 | 0.040 |
Why?
| | Cell Cycle Proteins | 1 | 2024 | 630 | 0.040 |
Why?
| | Gallbladder | 1 | 2019 | 15 | 0.040 |
Why?
| | Cholelithiasis | 1 | 2019 | 37 | 0.040 |
Why?
| | Hemodilution | 1 | 2019 | 11 | 0.040 |
Why?
| | Ecosystem | 1 | 2023 | 483 | 0.040 |
Why?
| | Choledocholithiasis | 1 | 2019 | 20 | 0.040 |
Why?
| | Cholecystectomy | 1 | 2019 | 63 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17438 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2019 | 183 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2022 | 485 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2025 | 2502 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2867 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3416 | 0.030 |
Why?
| | Bone Marrow | 1 | 2019 | 310 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2024 | 8391 | 0.030 |
Why?
| | Lymphocytes | 1 | 2019 | 379 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2026 | 5439 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2022 | 887 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2022 | 876 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1503 | 0.030 |
Why?
| | Risk Assessment | 1 | 2026 | 3712 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 989 | 0.030 |
Why?
| | Transcription Factors | 1 | 2024 | 1730 | 0.030 |
Why?
| | Cohort Studies | 1 | 2026 | 6077 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1133 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1998 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2023 | 2791 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11821 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 1982 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3206 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1792 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1537 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 2012 | 0.020 |
Why?
| | Germany | 1 | 2013 | 139 | 0.020 |
Why?
| | Chronic Disease | 1 | 2019 | 1827 | 0.020 |
Why?
| | Lung | 1 | 2025 | 4122 | 0.020 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 200 | 0.020 |
Why?
| | Risk Factors | 1 | 2026 | 10921 | 0.020 |
Why?
| | Pancreatic Neoplasms | 1 | 2019 | 944 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1942 | 0.010 |
Why?
| | United States | 1 | 2013 | 16136 | 0.010 |
Why?
|
|
Toland's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|